...
机译:P2.06-008期1/2期Mocetinostat和Durvalumab(Medi4736)在先进的实体瘤和非小细胞肺癌(NSCLC)中的研究
Montefiore Medical Center;
Mary Crowley Cancer Research Centers;
Medical Oncology Sarah Cannon Research Institute;
Medical Oncology Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
Division of Medical Oncology Thoracic Head and Neck Program University of Washington;
Hematology/Oncology/transplant University of Minnesota;
Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute;
Mirati Therapeutics;
Mirati Therapeutics;
Mirati Therapeutics;
Mirati Therapeutics;
Clinical Science Mirati Therapeutics;
Mirati Therapeutics;
Translational Oncology Research Laboratory UCLA Medical Center;
机译:P2.06-008期1/2期Mocetinostat和Durvalumab(Medi4736)在先进的实体瘤和非小细胞肺癌(NSCLC)中的研究
机译:不论PD-L1的状态如何,都观察到了durvalumab(MEDI4736)+ tremelimumab治疗对晚期非小细胞肺癌(NSCLC)患者的肿瘤反应
机译:一项I期研究旨在评估durvalumab(MEDI4736)联合tremelimumab在晚期实体瘤患者中的安全性和抗肿瘤活性
机译:使用有效的体内技术(Gilupi Cellcollector
机译:导致晚期非小细胞肺癌患者营养风险的症状:在晚期肺癌人群中进行营养筛查的重要性
机译:不论PD-L1的状态如何观察到durvalumab(MEDI4736)+ tremelimumab治疗对晚期非小细胞肺癌(NSCLC)患者的肿瘤反应
机译:不论PD-L1的状态如何,观察到durvalumab(MEDI4736)+ tremelimumab治疗对晚期非小细胞肺癌(NSCLC)患者的肿瘤反应